Acrivon Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
RA Capital Management acquired 3,888,888 shares of Acrivon Therapeutics in an at-the-market offering for approximately $7 million.
NASDAQ
RA Capital Management and its affiliates have reported a dilution of their beneficial ownership in Acrivon Therapeutics, Inc. to 21.6% due to an increase in outstanding shares, not through share disposition.